Comprehensive Educational Tools for Emergency Center Nurses: Managing Low-Risk DVT with Rivaroxaban

QUESTION

After graduating from nursing school and passing your boards, you accepted a position as an RN in the emergency center at Rasmussen General Hospital (RGH). In the weeks ahead, your emergency center plans to implement a new initiative where clients diagnosed with low-risk deep vein thrombosis (DVT) will be sent home on 3 months of oral anticoagulation therapy with rivaroxaban.

Historically, clients diagnosed with DVTs in the emergency center were admitted to the hospital’s observation unit. However, when surveyed about their experiences, many clients reported that this was costly, time-consuming, and inconvenient. Under RGH’s new program, emergency center nurses will be responsible for educating clients about their new medication and administering the first dose to the client before discharge.

As part of this new initiative, all emergency center nurses at RGH must be trained to properly educate these clients on all aspects of their new medication regimen. Because you have demonstrated a keen interest in pharmacology, your manager has asked you to develop the educational tools that will be used to train the nurses at RGH.

It’s worth noting that the standard dosing for all low-risk DVTs is as follows:

• 15 mg BID, 12 hours apart, for 21 days
• After 21 days, use 20 mg once per day.
• After 90 days, the client will follow up in the thrombosis clinic to evaluate if they meet criteria for discontinuing the medication.

Answer the questions below:

1. Pharmacotherapeutics
2. State the drug name and its therapeutic category.
3. Pharmacodynamics – how does this drug work to achieve its intended response?
4. Pharmacokinetics – how is this drug absorbed, distributed, metabolized, and excreted?
5. Discuss dosage, scheduling, route, and length of therapy.
6. Describe what clients can expect regarding their therapeutic response and when it should develop.
7. Introduce nondrug measures that clients can do to enhance their therapeutic response (e.g., specific diet to follow, exercise requirements, substances to avoid, special precautions to take, etc.).
8. Side Effects, Adverse Effects, and Interactions
9. Explain the symptoms of common side effects, and what clients can do to minimize any discomfort.
10. Explain the symptoms of any major adverse effects, and what clients should do if they experience them.
11. List the major adverse drug-drug interactions and drug-food interactions that clients need to be made aware of.
12. Follow-up Care
13. Provide information regarding when clients should call their doctor for advice (e.g., questions, non-urgent symptoms, unpleasant side effects, etc.).
14. Emphasize any symptoms for which clients should seek immediate care (e.g., when to go to the emergency center or call 911).

PS: References needed.

ANSWER

Comprehensive Educational Tools for Emergency Center Nurses: Managing Low-Risk DVT with Rivaroxaban

Introduction

The implementation of a new initiative at Rasmussen General Hospital’s (RGH) emergency center brings about a change in the management of low-risk deep vein thrombosis (DVT). Under this program, clients diagnosed with low-risk DVT will be sent home on a 3-month oral anticoagulation therapy with rivaroxaban. As an RN in the emergency center with a strong interest in pharmacology, the responsibility of developing educational tools for nurses to properly educate clients about this new medication regimen has been assigned. This essay outlines the essential information to be included in the educational tools, focusing on pharmacotherapeutics, pharmacodynamics, pharmacokinetics, dosage, therapeutic response, side effects, adverse effects, interactions, and follow-up care.

Pharmacotherapeutics

Drug Name and Therapeutic Category: The drug name is rivaroxaban, belonging to the therapeutic category of direct oral anticoagulants (DOACs).

Pharmacodynamics

Mechanism of Action: Rivaroxaban inhibits factor Xa, a key component of the coagulation cascade. By doing so, it prevents the formation of thrombin and subsequent clot formation.

Pharmacokinetics

Absorption: Rivaroxaban is rapidly absorbed from the gastrointestinal tract.
Distribution: It is highly protein-bound and widely distributed.
Metabolism: Rivaroxaban is metabolized in the liver via CYP3A4 and CYP2J2 enzymes.
Excretion: The majority of the drug is excreted through the kidneys as unchanged drug.

Dosage, Scheduling, Route, and Length of Therapy

Dosage: Initially, clients will take 15 mg BID (12 hours apart) for 21 days, followed by 20 mg once daily.
Route: Oral administration.
Length of Therapy: Clients will continue the therapy for 90 days, after which a follow-up in the thrombosis clinic will determine if discontinuation is appropriate.

Therapeutic Response

Clients can expect a reduction in clot formation and symptoms of DVT.
Therapeutic response should develop within days to weeks of starting treatment.

Nondrug Measures for Enhanced Therapeutic Response

Maintain a consistent diet and avoid drastic changes in Vitamin K intake.
Engage in regular exercise as approved by the healthcare provider.
Avoid activities that may increase the risk of injury or bleeding.

Side Effects, Adverse Effects, and Interactions

Common Side Effects: Clients may experience minor bleeding, gastrointestinal discomfort, or bruising.
Minimizing Discomfort: Applying direct pressure to minor cuts, taking the medication with food, and staying hydrated can help.

Major Adverse Effects: Clients should be aware of signs of major bleeding (e.g., blood in urine, stool, nosebleeds, etc.).
Immediate Action: If major bleeding occurs, clients should seek immediate medical attention.

Drug Interactions: Clients should be cautious with other anticoagulants, antiplatelet drugs, and NSAIDs.
Food Interactions: Grapefruit and grapefruit juice should be avoided.

Follow-up Care

Clients should call their doctor for advice regarding questions, non-urgent symptoms, or unpleasant side effects.
Immediate Care: Seek immediate medical care if there is uncontrolled bleeding, severe headaches, or sudden weakness.

Conclusion

The educational tools developed for emergency center nurses provide a comprehensive understanding of managing low-risk DVT with rivaroxaban. By focusing on pharmacotherapeutics, pharmacodynamics, pharmacokinetics, dosage, therapeutic response, side effects, adverse effects, interactions, and follow-up care, these tools empower nurses to educate clients effectively. Ensuring that clients are well-informed about their medication regimen, potential side effects, and appropriate responses to adverse events enhances patient safety and adherence, ultimately contributing to improved outcomes in the management of low-risk DVT.